Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate offunctional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Biotechnology

Health Care

Bluejay Therapeutics

Bluejay Therapeutics' headquarters in San Francisco, CA, United States

Description

People (5)

Jeff Zablocki

Dmitry Koltun

Nancy Shulman M.D.

Travis Mowbray

Susanna Tan

Jobs